tags

Cosmetics
China Cosmetic Testing Requirements: CMA, CNAS, and ISO 17025 Explained

Not all cosmetic test reports are created equal: some are rejected by regulators, and some aren’t internationally recognized. Choosing the wrong laboratory can delay your product launch or even block market entry entirely. This article explains the differences between CMA, CNAS, and ISO 17025 accreditation, why they matter for cosmetic testing in China, and how to select the right lab for regulatory compliance.

South Korea Proposes Ban on IP-Infringing Cosmetics Alongside New Export Support

On April 20, 2026, the Korea Cosmetic Association (KCIA) issued Notice No. 4-161, forwarding document No. 2757 from the Ministry of Food and Drug Safety (MFDS) Cosmetic Policy Division. The notice announces a legislative proposal initiated by Representative Baek Jong-heon to partially amend the Cosmetics Act, and invites public comments. The core objectives of the proposed amendment are to strengthen regulatory measures against the sale of "IP-infringing cosmetics" and to establish an export support mechanism. The KCIA feedback deadline is April 23, 2026.

China IECIC Update: Ingredient Name Changes and International Discrepancies to Note

On April 13, 2026, China’s National Medical Products Administration (NMPA) carried out the fourth dynamic adjustment to the Inventory of Existing Cosmetic Ingredients in China, involving a total of 50 records. For certain ingredients revised in IECIC I, the updated names differ from those currently listed in the EU Cosmetic Ingredient Catalogue ((EU) 2025/1175) and the US INCI database.

INCI Names and CAS Numbers: Have You Registered the “Birth Certificates” for New Cosmetic Ingredients?

In the cosmetics industry, INCI names and CAS numbers are regarded as the "birth certificates" for new ingredients. These identifiers not only establish the identity of the ingredients but also facilitate their recognition and communication in the global market. This article explores the definitions, application processes, and international market applications of INCI names and CAS numbers, aiming to help cosmetic companies better understand their significance.

Summary Report on Cosmetic Supervision and Sampling Inspection-February 2026

In February 2026, the National Medical Products Administration, along with the Medical Products Administrations of Guangxi Zhuang Autonomous Region, Hunan Province, and Beijing, issued announcements regarding cosmetic supervision and sampling inspections. A total of 71 batches of products were found to be non-compliant. This summary of the announcements aims to help enterprises stay informed of evolving regulatory trends and strengthen their quality management and compliance awareness.